RxDoctor Payments Data

Emanuel Ebin, MD

Clinical Cardiac Electrophysiology · Coon Rapids, MNNPI 1609286236

Payments from drug & device makers

What this record shows

This record is dominated by grants: $45,294 of the $49,197 with a category attached, or 92.1%. Medtronic accounts for 94.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $25,164 and has fallen 93.2% since, to $1,716 in 2025.

$49,197in general payments, 2019–2025

Across 68 payments — averaging $723.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$47K
  • Abbott$2K
  • Biotronik Inc.$392
  • Boston Scientific$259
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$76
  • Novartis$44
  • plus $164 from 7 others

What the payments were for

  • Consulting fees$4751%
  • Grants$45,29492%
  • Travel & lodging$4591%
  • Food & beverage$2,9056%
  • Education$640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,197 in reported general payments places this provider in the 80th percentile of 72 clinical cardiac electrophysiology providers in Minnesota.

See all clinical cardiac electrophysiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$150,146
Medicare patients
1,238
Services billed
2,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$94,395
XareltoRivaroxaban25$36,038
EntrestoSacubitril/Valsartan20$26,877
Flecainide Acetate29$1,231
Metoprolol Succinate50$851
SotalolSotalol Hcl26$838
Atorvastatin Calcium33$677
Rosuvastatin Calcium21$388
Mupirocin40$302
Warfarin Sodium11$280
Lisinopril22$261
Amiodarone Hcl23$260
Furosemide21$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$44$26,87720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 72 clinical cardiac electrophysiology providers in Minnesota.

Other clinical cardiac electrophysiology in Coon Rapids

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →